We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App





Vital Technological Breakthrough Could Help Diagnose Long-Term Effects of COVID-19

By LabMedica International staff writers
Posted on 01 Sep 2022
Print article
Image: A new diagnostic tool will aid the diagnosis of debilitating symptoms of long COVID-19 (Photo courtesy of Pexels)
Image: A new diagnostic tool will aid the diagnosis of debilitating symptoms of long COVID-19 (Photo courtesy of Pexels)

With no current framework or diagnostic tools, patients suffering from the effects of COVID-19 and long COVID-19 present general practitioners with a major health challenge. Now, a new discovery will aid the diagnosis of debilitating symptoms that can include severe headaches, extreme exhaustion, heart palpitations and brain fog. The discovery comes in the form of a new diagnostic tool that could be easily deployed in medical practices across the world, at low cost.

Eighteen months ago, researchers at Murdoch University (Perth, Australia) used multi-million-dollar nuclear magnetic resonance (NMR) technology to identify new diagnostic molecular biomarkers that tell if someone has the disease, without the need to detect the disease itself. They then used this work to develop an inexpensive clinical NRM that general practitioners can use to detect vital blood markers to predict the long-term effects of the conditions. The technology uses a specially designed set of radio pulses to extract signals from highly specific biomarker signals (from inflammatory glycoprotein markers and fats bound to lipoproteins) that gives a rapid diagnosis in approximately a minute. The researchers believe that their findings represent a translational triumph that will ultimately benefit COVID-19 patients in clinics throughout the world, as well as have the possibility for application across many other diagnostic areas including cardiovascular disease.

“We only discovered these signals about 18 months ago using a more expensive NRM instrument, but with some pulse sequence modifications, we are now able to get identical results on small machines that costs one tenth of the price,” said Professor Jeremy Nicholson, Director of the ANPC and Pro Vice Chancellor for the Health Futures Institute. “We think this technology (low field NMR spectroscopy) will probably have many other clinical applications in the future and may be of particular value in monitoring some of the residual effects of long COVID in individual patients.”

“It ticks all the boxes for a successful translational technology: low costs, low maintenance, no specialist required and no need for complex algorithms to understand the data,” said Professor Julien Wist from the ANPC who believes the technological advancement has many benefits, including cutting costs.

 

 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.